Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Novel Therapeutic Effect of Phosphoinositide 3-Kinase-γ Inhibitor AS605240 in Autoimmune Diabetes
Jamil Azzi, Robert F. Moore, Wassim Elyaman, et al.
Diabetes (2012) Vol. 61, Iss. 6, pp. 1509-1518
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

PI3K signalling in inflammation
Phillip T. Hawkins, Len Stephens
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2014) Vol. 1851, Iss. 6, pp. 882-897
Open Access | Times Cited: 480
Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kγ mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells
Hongwei Zhang, Jinjiao Hu, Ruoqiu Fu, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 215
Mechanisms of development of multimorbidity in the elderly
Peter J. Barnes
European Respiratory Journal (2015) Vol. 45, Iss. 3, pp. 790-806
Open Access | Times Cited: 176
Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression
Yawara Kawano, Oksana Zavidij, Jihye Park, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 6, pp. 2487-2499
Open Access | Times Cited: 92
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies
Kamal D. Puri, Michael R. Gold
Frontiers in Immunology (2012) Vol. 3
Open Access | Times Cited: 97
Advances in the cellular immunological pathogenesis of type 1 diabetes
Min Li, Lujun Song, Xinyu Qin
Journal of Cellular and Molecular Medicine (2014) Vol. 18, Iss. 5, pp. 749-758
Open Access | Times Cited: 76
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 3, pp. 141-158
Closed Access | Times Cited: 7
The rise, fall, and resurgence of immunotherapy in type 1 diabetes
Moufida Ben Nasr, Francesca D’Addio, Vera Usuelli, et al.
Pharmacological Research (2014) Vol. 98, pp. 31-38
Closed Access | Times Cited: 61
Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection
Clovis S. Palmer, Gabriel Duette, M. Wagner, et al.
FEBS Letters (2017) Vol. 591, Iss. 20, pp. 3319-3332
Open Access | Times Cited: 58
Actuation of single downstream nodes in growth factor network steers immune cell migration
Dhiman Sankar Pal, Tatsat Banerjee, Yiyan Lin, et al.
Developmental Cell (2023) Vol. 58, Iss. 13, pp. 1170-1188.e7
Open Access | Times Cited: 13
A systems‐level study reveals host‐targeted repurposable drugs against SARS‐CoV‐2 infection
Fangyuan Chen, Qingya Shi, Fen Pei, et al.
Molecular Systems Biology (2021) Vol. 17, Iss. 8
Open Access | Times Cited: 31
Ras suppression potentiates rear actomyosin contractility-driven cell polarization and migration
Yiyan Lin, Dhiman Sankar Pal, Parijat Banerjee, et al.
Nature Cell Biology (2024) Vol. 26, Iss. 7, pp. 1062-1076
Closed Access | Times Cited: 4
Investigation of the Interaction Between 4‐Thiazolidinone Derivatives and SARS‐CoV‐2 Mpro Using Spectroscopy and Microscale Thermophoresis
Leyao Chen, N. Wang, Xiaoyu Chang, et al.
ChemistrySelect (2025) Vol. 10, Iss. 15
Closed Access
PI3K inhibitors as potential therapeutics for autoimmune disease
Jennifer Ball, Sophie Archer, Stephen G. Ward
Drug Discovery Today (2014) Vol. 19, Iss. 8, pp. 1195-1199
Open Access | Times Cited: 32
Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
Mayuko Uehara, Martina M. McGrath, Shunsuke Ohori, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 29
Rev-erbα activation down-regulates hepatic Pck1 enzyme to lower plasma glucose in mice
Xue Yuan, Dong Dong, Zhijie Li, et al.
Pharmacological Research (2019) Vol. 141, pp. 310-318
Closed Access | Times Cited: 26
Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration
Michiko Horiguchi, Yuki Oiso, Hitomi Sakai, et al.
Journal of Controlled Release (2015) Vol. 213, pp. 112-119
Closed Access | Times Cited: 25
A Strong Adhesive Biological Hydrogel for Colon Leakage Repair and Abdominal Adhesion Prevention
Qijiang Mao, Zhengze Huang, Yiyin Zhang, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 28
Closed Access | Times Cited: 7
PI3Kγ (Phosphoinositide 3-Kinase-γ) Inhibition Attenuates Tissue-Type Plasminogen Activator–Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke
Rong Jin, Adam Y. Xiao, Jarvis Li, et al.
Hypertension (2018) Vol. 73, Iss. 1, pp. 206-216
Open Access | Times Cited: 22
Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes
Sungwook Jung, Moufida Ben Nasr, Baharak Bahmani, et al.
Advanced Materials (2023) Vol. 35, Iss. 40
Closed Access | Times Cited: 6
La inhibición de la PI3Kγ protege contra la miocardiopatía diabética en ratones
Angelo Maffei, Giuseppe Cifelli, Raimondo Carnevale, et al.
Revista Española de Cardiología (2016) Vol. 70, Iss. 1, pp. 16-24
Closed Access | Times Cited: 15
Recent Discovery of Phosphoinositide 3-Kinase γ Inhibitors for the Treatment of Immune Diseases and Cancers
Xiaqiu Qiu, Yucheng Tian, Zhuangzhuang Liang, et al.
Future Medicinal Chemistry (2019) Vol. 11, Iss. 16, pp. 2151-2169
Closed Access | Times Cited: 15
Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.
Ramesh Alluri, Sivamallikarjuna Reddy Ambati, Kasiviswanth Routhu, et al.
PubMed (2020) Vol. 19, pp. 71-85
Closed Access | Times Cited: 14
Phosphoinositide 3‐kinase/protein kinase B inhibition restores regulatory T cell's function in pulmonary sarcoidosis
Bin Zhang, Qianqian Dai, Xuguang Jin, et al.
Journal of Cellular Physiology (2019) Vol. 234, Iss. 11, pp. 19911-19920
Closed Access | Times Cited: 12
AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
Jiacheng Sun, Guoping Cai, Jinlong Shen, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 1275-1288
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top